Clinical trials: Chronic Obstructive Pulmonary Disease Exacerbation
- Condition Chronic Obstructive Pulmonary Disease Exacerbation
- Funder type Industry (pharma, biotech, devices)
Pulmonary Disease, Chronic Obstructive
SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease
This is a comparator study to assess the relative efficacy of the combination product fluticasone propionate/salmeterol 50/500 and tiotropium bromide on the rate of exacerbations of chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT00361959
- Testing
- Tiotropium bromide 18mcg, Fluticasone propionate/ salmeterol combination 50/500mcg
- Where
- 166 sites in Austria, Belgium and 18 more
- Volunteers
- 1,270 people
- Sponsor
- GlaxoSmithKline
Allergic Asthma
A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma
Study JSP-CP-012 is designed as a proof of concept, parallel-group, single dose, double blind, placebo-controlled study using an allergen challenge model.
- Trial name
- NCT06592768
- Testing
- Briquilimab
- Where
- 6 sites in Canada
- Volunteers
- 17 people
- Sponsor
- Jasper Therapeutics, Inc.
Bronchitis, Chronic
AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs
The objective of this global non-interventional study is to evaluate the impact of Acute Exacerbation of Chronic Bronchitis(AECB) on the patient and the community as well as the safety and effect of a treatment with Moxifloxacin…
- Trial name
- NCT00846911
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- 8 sites in Albania, Bosnia and Herzegovina and 6 more
- Volunteers
- 2,672 people
- Sponsor
- Bayer
Bronchitis
Outcome Study to Evaluate Klaricid XL® (Clarithromycin Modified Release) in Patients With Acute Exacerbation of Chronic Bronchitis
The objective of this study was to evaluate the role of Klaricid XL (clarithromycin modified release) in the treatment of acute exacerbation of chronic bronchitis (AECB) and its impact on improving the quality of life.
- Trial name
- NCT01354938
- Testing
- Clarithromycin modified release 500 mg
- Where
- 28 sites in Pakistan
- Volunteers
- 220 people
- Sponsor
- Abbott
Pulmonary Disease, Chronic Obstructive
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in…
- Trial name
- NCT02296138
- Testing
- olodaterol, tiotropium
- Where
- 818 sites in United States, Argentina and 49 more
- Volunteers
- 7,903 people
- Sponsor
- Boehringer Ingelheim
Chronic Bronchitis
SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)
In this study data of patients with moderate or severe acute exacerbations of chronic bronchitis (AECB) were collected. There were two different cohorts which were compared (Moxifloxacin and other antibiotics) concerning…
- Trial name
- SYMPROVE III (NCT00879008)
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- Germany
- Volunteers
- 345 people
- Sponsor
- Bayer
Pneumonia, Bronchiolitis
Diagnosing Respiratory Disease in Children Using Cough Sounds 2
The purpose of this prospective study is to evaluate the efficacy of the ResAppDx software application in the diagnosis of childhood acute respiratory disease, including pneumonia, bronchiolitis, asthma/reactive airways disease…
- Conditions
- Pneumonia, Bronchiolitis, Asthma Exacerbation, Croup
- Trial name
- SMARTCOUGH-C-2 (NCT03392363)
- Testing
- Recordings of Infants and Children's Cough Sounds
- Where
- 3 sites in United States
- Volunteers
- 1,470 people
- Sponsor
- ResApp Health Limited
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)
The aim of the study is to compare the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00297115
- Testing
- Roflumilast
- Where
- 287 sites in United States, Canada and 6 more
- Volunteers
- 1,568 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this trial is to determine whether treatment with tiotropium (18 mcg) capsule once daily via the HandiHaler reduces the proportion of patients with COPD experiencing an exacerbation and the proportion of…
- Trial name
- NCT00274547
- Testing
- Tiotropium
- Where
- 26 sites in United States
- Volunteers
- 1,829 people
- Sponsor
- Boehringer Ingelheim
Respiratory Failure, Neuromuscular Disease
Ventilator Monitoring in Early Exacerbation Detection
The aim of this study is to determine whether respiratory disease exacerbations (a sudden worsening of symptoms) can be predicted by variables that are monitored by non-invasive ventilators (small machines that assist breathing)…
- Conditions
- Respiratory Failure, Neuromuscular Disease, Chest Wall Disorder, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT01644162
- Testing
- iVAPS ventilation
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- ResMed
COPD Exacerbation
Comparative Effectiveness of Symbicort vs. Spiriva Among COPD Patients
This study is intended to evaluate treatment effectiveness with budesonide/formoterol (BFC) and tiotropium tromide in patients new to ICS/LABA combination and LAMA therapies.
- Trial name
- NCT01917643
- Volunteers
- 2,396 people
- Sponsor
- AstraZeneca
Chronic Bronchitis, Disease Exacerbation
VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis
This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from an acute exacerbation of chronic bronchitis and take at least one dose of…
- Trial name
- VICTOR (NCT00876577)
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- China
- Volunteers
- 1,206 people
- Sponsor
- Bayer
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)
The aim of the study is to investigate the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00297102
- Testing
- Roflumilast
- Where
- 179 sites in United States, Australia and 9 more
- Volunteers
- 1,523 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Etiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) in Japan
The purpose of this prospective, epidemiological, cohort study is to evaluate the lung microbiome in stable-state chronic obstructive pulmonary disease (COPD) in Japanese participants
- Trial name
- NCT03957577
- Testing
- Prospective observational cohort study
- Where
- 13 sites in Japan
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
- Trial name
- SPARK (NCT01120691)
- Testing
- QVA149, NVA237, tiotropium
- Where
- 342 sites in United States, Argentina and 26 more
- Volunteers
- 2,224 people
- Sponsor
- Novartis Pharmaceuticals
COPD Exacerbation
Non-contact Proactive Remote Monitoring of COPD Exacerbations
The goal of this observational study is to determine if a COPD exacerbation can be detected early in its onset. The main questions it aims to answer are: Can an exacerbation be detected before the person recognizes they are…
- Trial name
- DetectEx (NCT05598983)
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- Life Detection Technologies
COPD, COPD Exacerbation
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.
- Trial name
- TRITON (NCT04320342)
- Testing
- Beclomethasone Dipropionate, Glycopyrronium Bromide, Formoterol Fumarate
- Where
- 436 sites in United States, Argentina and 8 more
- Volunteers
- 3,406 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Bronchitis
A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis
Identifying the role of antibiotics in the treatment of subjects with a microbiologically documented acute exacerbation of chronic bronchitis (AECB) is the purpose of this clinical trial.
- Trial name
- NCT00255983
- Testing
- Faropenem medoxomil
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- Replidyne
Asthma, Copd
Inhaler Trainer Efficacy Study
This will be a randomized, controlled, clinical trial. The investigators aim to determine the feasibility of and efficacy of the Inhaler Trainer Device for ongoing inhaler skill training.
- Conditions
- Asthma, Copd, Acute Exacerbation of COPD
- Trial name
- NCT06461403
- Testing
- Inhaler Trainer System, Initial Inhaler Use Assessment, Inhaler Use Instruction
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Koronis Biomedical Technologies
COPD Exacerbation
A Feasibility Study of Wearable Device in Assessing Respiratory Condition Change of Patients With Exacerbation of COPD
The study will include daily SenseGuard measurement of patients hospitalized with exacerbations of COPD. from admission to discharge.
- Trial name
- NCT05153122
- Testing
- SenseGuard
- Where
- 2 sites in Germany, Israel
- Volunteers
- 15 people
- Sponsor
- NanoVation